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COMPARATIVE ANALYSIS OF THE DISSOLUTION PERFORMANCE OF 
ASPIRIN TABLETS IN THE USP APPARATUS 2 AND IN A MINIVESSEL 
DISSOLUTION SYSTEM 
 by  
Annmarie C Walker 
Dissolution testing is a critical component of quality control procedures in the 
pharmaceutical industry in order to ensure that the final solid dosage forms have consistent 
dissolution properties. Dissolution tests are also routinely conducted to evaluate the in-vitro 
performance of solid dosage forms during pharmaceutical development, to aid in the 
behavior of formulations, and to optimize drug release from dosage forms. 
The use of compendial dissolution test apparatus and techniques, such as the USP 2 
(Paddle), to characterize the dissolution performance of oral drug delivery system is an 
established area of pharmaceutical science.  However, this method is not always appropriate, 
particularly in dissolution tests that involves the use of very small tablets or when there is 
not enough drug substances available for appropriate test in the USP 2 system, particularly 
during the early stages of drug development. 
Mini vessel systems, i.e., a small-volume dissolution apparatus, require a small drug 
amount and utilize a small volume of dissolving medium.  Therefore, they are an emerging 
technology in the pharmaceutical industry that can be used to overcome the limitations 
associated with the USP 2-based dissolution testing method.  Mini vessels offer cost effective 




smaller volumes of media.  Despite the industrial relevance of mini vessels only a small 
number of studies on mini vessel dissolution systems have appeared in the literature. 
In this work, a commercially available non-compendial Minivessel Dissolution 
System and a USP 2 dissolution system were used to conduct dissolution tests using two 
different dosage forms, both containing aspirin as the Active Pharmaceutical Ingredient 
(API).  Specifically, dissolution tests were conducted in the standard USP 2 with coated 325-
mg aspirin caplets and with half doses in the USP 2 and in the Minivessel.  Additionally, 81-
mg enteric-coated delayed release aspirin tablets were used.  Five 81-mg tablets were used 
in simultaneously used in dissolutions test in the USP 2 using 500 ml of dissolution medium 
while a single 81-mg dose and 100 ml of medium were used in the Minivessel in order to 
achieve similarity of surface area of tablets to volume of medium in both systems.  
Experiments in the USP 2 were conducted at compendial speeds of 50, 75, and 100 rpm.  
Minivessel experiments were conducted at different agitation speeds, i.e., 50, 75, 100, 125, 
150 rpm, as well as at the agitation speeds equal to 86.2, 109.7, and 129.2 rpm since at these 
agitation speeds the tablet-medium mass transfer coefficients were previously predicted to 
be similar to those in the USP 2 at 50, 75, and 100 rpm, respectively.   
The dissolution curves in the Minivessel and in the USP 2 were compared and it was 
found that operating the Minivessel as predicted to achieve similar mass transfer coefficients 
in the USP 2 produced similar dissolution curves in both systems.  The comparison was 
additionally quantified by using the difference factor f1 and the similarity factor f2 
recommended by the Food and Drug Administration (FDA). 
It can be concluded that appropriately operating Minivessel can result in dissolution 




significant importance to dissolution scientists in the pharmaceutical industry and help them 
operate mini vessels, especially during the early stages of drug development, so as to predict 
future dissolution profiles of the same drug product during commercialization, when the USP 
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Dissolution can be defined in a narrow sense as the process by which a solid substance is 
incorporated into a solvent to form a solution. However, in a broader sense it is more than 
a single measurement of solubility rate and can be better described as a physical test to 
predict the drug release from a dosage form for given area for a precise time. 
Dissolution testing of solid dosage forms is a laboratory test process that attempts 
to replicate in vitro the complex in vivo process associated with tablet disintegration and 
dissolution in the gastro-intestinal tract.  Additionally, this is a test that pharmaceutical 
companies typically conduct on oral dosage formulations to determine compliance and to 
release products for distribution and sales.  The United States Pharmacopeia (USP) lists 
several standardized dissolution testing methods and apparatuses (USP 39-NF 34, 2016).  
The most widely used of these devices is the USP Dissolution Testing Apparatus 2, 
typically referred to as USP 2 (Cohen et al., 1990; Cox et al., 1984; Mauger et al., 2003; 
Moore et al., 1995; Moore and Flanner, 1996; U.S FDA, 1997). 
Common dosage forms such as tablets, capsules, suspensions, suppositories, 
chewable and transdermal, typically contain milligram levels of the Active Pharmaceutical 
Ingredient (API) and are easily quantified in dissolution medium from 500 mL to 4L 
depending upon on the dosage form and its respective method. Dissolution rate is also the 
limiting step for drug absorbed in the systemic circulation for immediate release dosage 
forms. Dissolution test for these types of drugs are performed using the USP apparatus, 
namely the basket, paddle, rotating cylinder and flow through cell. 
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Newer designs for the testing of these dosage forms include the Minivessel 
apparatus. Dissolution of typical high potency, low dose compounds need a reduction in 
vessel volume, further accompanied by modification of the apparatus design due to some 
drawbacks in the official compendial apparatus. This include inability to maintain 
quantitative levels of analyte during dissolution test. 
The use of small volume dissolution apparatus satisfies the need to give reliable 
correct data, for decision making during early development stages of drugs. They also 
provide quality control at the time when the formulation reaches scale up and provides 
assurance of product stability. 
The Minivessel is based on the USP paddle set up, but the size is scaled down to 
exactly 1/3 of the USP and 40% with respect to vessel volume and impeller sizes. The 
volume used is approximately 250-mL and the working volume is typically 100-mL. 
The main advantage of Minivessel are that it requires a small dose of a drug that is 
used for paddle apparatus, smaller volumes of media used offer various advantages in terms 
of substance, analytical and material cost savings. This set up is also a promising alternative 
in the case of high-potency drugs. 
Dissolution testing is a requirement for all solid dosage forms, and is used 
throughout the development life cycle for product release and stability testing. The 
dissolution test is the most important analytical test for detecting physical changes in an 
API and in the formulation. Dissolution testing has more and more evolved to establish 
relationships with in vivo performance or with manufacturing Critical Quality Attributes 
(CQA) in the scope of Quality by Design (QbD) [1].  
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At early stages of the drug the development processes in vitro dissolution testing 
underpins the optimization of drug release from a given formulation. To aid with dosage 
form optimization the dissolution testing is a standardized method for measuring the rate 
of drug release from a given dosage form, while at later stages [4,5].  
In short, for the development and validation of dissolution test procedure, the 
foremost requirement is to ascertain that the apparatus and procedure are capable of 
simulating and in-vivo environment through which the product will pass. At present, the 
industry standard dissolution testing methodologies are the Pharmacopeial, United States 
Pharmacopeia Apparatus 1, (basket), and apparatus 2, (paddle) [2,3,4]. 
The USP Apparatus 2 and its accompanying test are routinely used in the 
pharmaceutical industry to help formulate solid drug dosage forms, particularly for 
immediate release (IR)of the. solid dosage form, [2,6]. 
Also during product development, dissolution testing consists of two components. 
This involves preparation of the test drug product followed by the analysis of the sample 
collected during dissolution test. The standard dissolution apparatus such as USP 2 is used. 
Surprisingly these apparatuses do not provide the necessary product medium interaction. 
This is due to the lack of adequate stirring and mixing within the vessel. This lack of stirring 
and mixing appears to cause difficulties, stagnation and result in errors in the development 
of proper dissolution method through variability. Extensive work has been done that 




Sample analysis, are done primarily by chromatographic or spectrophotometric 
techniques. The two components of the dissolution test, sample preparation and assay are 
separated by a filtration step. Filters must be validated to prove their efficiency in removing 
undissolved Active Pharmaceutical Ingredient (API) from the sample and to verify that 
they do not absorb dissolved API, which affects the integrity of the sample concentration. 
The first step taken to overcome concentration and sensitivity issues is usually modification 
of analytical method by taking advantage of a larger path length for spectrometer or larger 
injection volume for high performance liquid chromatography, (HPLC). When success 
with these techniques are limited, the focus on the dissolution apparatus where a reduction 
in media volume may be a more rugged solution becomes relevant. [23]. 
Only a few of the compendial dissolution and drug release apparatus are designed 
for low dose compounds and volume requirements less than 100ml presents additional 
challenges to the traditional paddle and basket apparatus. Rugged dissolution methods 
should quantify the low levels of analyte accurately and precisely especially in the initial 
stages of analytical concentration in the presence of reliable and consistent agitation is the 
primary requirement of any dissolution test but demands extreme precision in low volume 
conditions to ensure data accuracy [23]. 
The dissolution apparatus must operate under conditions of controlled temperature, 
agitation rate and precise hydrodynamics and volume. To maintain precise hydrodynamics 
the apparatus must maintain an overall physical uniformity and alignment throughout the 
test. Standard dissolution apparatus may be obtained from manufacturers that produce the 




For low dose concentrations of API, official compendial is seen to be incapable of 
maintaining quantitative levels of an analyte during dissolution of oral dosage units 
containing microgram or nanogram levels. [16,17] Accordingly Crail et al stated,” It has 
been our experience that the apparatus 2 is suitable for the evaluation of the dissolution 
characteristics in developing a dissolution method for a new propriety tablet containing 
200 microgram actives the early dissolution points could not be quantified using the current 
this assayed method”. To increase the drug concentration several options were considered. 
The first was to use multiple tablets in a single vessel using 500ml to 900ml of media, 
another option was to use a conversion a 200ml vessel offered by Van Kel Technologies, 
[17]. 
Dissolution of typical high potency low dose compounds may require reduction in 
vessel volume accompanied by an alteration in apparatus design due to limitations in 
detection and quantification. if a reduction in volume accompanied by an alteration, the 
apparatus should maintain the same degree of precision and alignment required for any 
other compendial dissolution apparatus. Small volume apparatus is not desired only for 
high potency, low dose formulations, but also in cases were specific physiological 
environment is a requirement Specifically for some biorelevant studies, during drug 
formulation, dissolution should be ideally conducted in a specific medium, such as an 
animal gastrointestinal medium with a similar dissolution medium as in the animal 
physiology, [6,12,17,]. 
To address the issues in industry, practice the standard (USP2) dissolution method 
has been modified and a small volume dissolution vessel with a mini paddle has been 
suggested as an alternative to standard dissolution equipment in early stages development 
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studies that require large volumes of biorelevant medium. This can be very expensive and 
there may be limitations of large sample sizes or active drug availability in early stages of 
drug development [11]. 
The solubility and dissolution rate of a drug can be linked to bioavailability in many 
cases. To achieve physiologically relevant results, it is necessary to use well designed test 
set up. The choice of the most appropriate hydrodynamics is essential for development of 
a biorelevant dissolution method. The modification of existing system and new apparatus 
is proposed in specific cases. When tablets contain very small amounts of active ingredient 
or when extended release tablets are tested in which small amounts are released and may 
be difficult to detect using conventional methods [12,13, 17,21]. 
The Minivessel dissolution system consist of a small vessel with typically working 
volume of 100ml, and a small size impeller in the shape of that used in USP2.  However, 
such Minivessel dissolution apparatus and the associated dissolution method are not yet 
included in the USP Pharmacopeia although Section (1902) mentions that this mini paddle 
and Minivessel may have some utility with proper justification, qualification, 
documentation, and superiority to apparatus 2 standard equipment, and they may be 
considered for low dosage strength products. During development of the small volume 
method, it is important to consider that the current small or low volume vessels are non-
compendial. The commercially available vessels are well defined, but there are still 
differences from supplier to supplier [13, 23]. It was demonstrated that differences in the 
actual compendia apparatuses existed between suppliers even if within the standardized 
dimensions and that those differences marginally affected the results [23].  
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In case of small volume vessels there is no currently fixed dimension between 
suppliers. This means that each investigation should be carry out specifically and that 
transfer is more complicated than using the classical pharmacopeia one-liter vessel. Small 
volume USP2 has gained popularity due to the reduced mass of material required, whilst 
retaining the analytical methodology and discriminating power of the conventional 
apparatus. Furthermore, the small volume apparatus may be beneficial in the development 
of biorelevant methods, particularly for pediatric population [11,12] 
The dissolution apparatus has been modified to provide for testing in in smaller 
volumes of dissolution media. With the modification, physical parameters critical to the 
ruggedness of the dissolution must also be maintained. In the current state, the apparatus 
possesses individual limitations when attempting to conduct small volume dissolution, 
[23]. 
Although the Minivessel is miniaturized version of the conventional apparatus there 
is still a need to analyses the hydrodynamics, since the miniaturized system do not exactly 
replicate the conditions of the standard paddle system, nor the conditions in the GI Tract 
[11]. 
Developing literature on the Minivessel generally quite limited. This implies some 
important issues are still to be addressed that includes apparatus calibration, reliability, 
reproducibility and method validation before the apparatus can be widely accepted. In 
addition to understand how the dissolution test conducted in Minivessel compare to those 
obtain in standard USP2, [6,12-13,23]. This requires more important understanding of the 
dissolution rate and drug release. In the current regulatory environment, our dissolution 
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methods must be accurate, sensitive and specific and the reproducibility of the test method 
employed must be established, verified and documented [14].  
Despite progress in dissolution testing, little information is available on mini vessel 
systems in general.  More importantly, it is still unclear how dissolution data obtained 
during product development in such non-compendial mini vessels can be interpreted to 
predict how the drug product would dissolve in a compendial dissolution testing apparatus 
such as the USP 2 during commercial manufacturing. 
Recently, a study conducted by our research group (Wang et al., 2017) has resulted 
in computational predictions of the operating conditions under which Minivessel should be 
operated in order to generate dissolution profiles that are similar to those expected in USP 
2 system.  However, those predictions were not supported by experimental evidence.  
Therefore, there is still a need to determine whether the approach proposed by Wang et al. 
is valid as far as being able to predict the corresponding dissolution profiles in USP 2 
systems.  More in general, there is the need to compare actual dissolution profiles in the 
two systems to establish how dissolution profiles in Minivessel compare with those in USP 
2 systems.  Then, by either experimentation alone, or possibly through experiments 
conducted according to model predictions, it may be possible to determine how Minivessel 
tests should be conducted to replicate results in the USP 2.  The present work was 
conducted to partially address this question by using a simple drug product, i.e., aspirin 
caplets and tablets, and experimentally testing their dissolution characteristics in both the 








BACKGROUND AND OBJECTIVE OF THIS WORK  
 
Accurate concentration of analyte and consistent agitation are primary requirements for 
any dissolution test. However, for small volume dissolution, the requirement for extreme 
precision to ensure data accuracy is also essential. The standardization of the miniaturized 
equipment is critical for subsequent scale-up to the standard USP 2 and for future 
acceptance by regulatory agencies if this method is also being used for quality control.  
However, before Minivessel can acquire wider acceptance the dissolution profiles that they 
generate must somehow be related to those obtained in the standard USP 2 systems. 
The literature review above has shown that the Minivessel is a device often used to 
provide testing in smaller volume of dissolution medium.  Given the geometric differences 
between the USP 2 and the Minivessel, one can expect that the dissolution profiles obtained 
in the Minivessel will not necessarily be comparable with those generated in the standard 
USP 2 setup [23]. It may be still possible to determine the operating conditions in the 
Minivessel (mainly the agitation speed and the characteristics of the tablet to be used in 
this apparatus) that can result in dissolution profiles vs. time that are similar or have strong 
analogy to the dissolution profiles obtained with an actual commercially-ready tablet in a 
USP 2.  This can be achieved by conducting enough experiments in both systems under 
different operating conditions until dissolution profile similarity is achieved. A better 
approach is to have some insight into the process that can be used to provide guidance on 
how to conduct experiments in order to achieve similarity in dissolution profiles, and only 
then test experimentally the validity of this approach. 
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Recent work on the hydrodynamics of Minivessel and the USP 2 by our group has 
resulted in a detailed mapping of the velocity profiles in both systems (Wang et al., 2017).  
In addition, this knowledge has been used to generate predictions on what hydrodynamic 
conditions should be maintained in the lower portion of the two systems, i.e., in the region 
where the dissolving tablet is, in order to achieve similar values of the tablet-medium mass 
transfer coefficients.  According to that work, a non-disintegrating tablet in the USP 2 and 
in the Minivessel should experience the same mass transfer coefficient kprd if the two 
systems are operated at the agitation speeds N reported in Table 2.1. [26] 
In general, a simple mass balances for the dissolving drug in a dissolution system, 
results in the following equation for the drug fractional mass released from the tablet 
















 Where MD is the mass of drug released at any time t, MT is the total mass of drug initially 
in the tablet, kprd mass transfer coefficient if the two systems operates at agitation speeds 





Table 2.1 Predictions of the agitation speeds in a mini vessel required to achieve the same 
mass transfer coefficients for a salicylic acid tablet as in a USP 2 system operating at a 
given agitation speed (50, 75 and 100 rpm). (Wang et al., 2017). 





Source: Wang, B., Bredael, G. and Armenante, P. M.  (2017) Prediction of the Operating Conditions for 
Similarity of Dissolution Performance in a Mini Vessel and a USP 2 Dissolution Testing System Using 
Hydrodynamic Comparison, Intern. J. Pharm., submitted and under review 
 
In order for MD/MT to exhibit the same profile as a function of time in both the USP 2 and 
the Minivessel, the term (kprd A(t)/VL) must be the same in both systems. Similarity of kprd is 
predicted to be achieved if the two systems are operated as shown in Table 2.1 and Figure 
2.1.  For non-disintegrating tablet the initial ratio A/VL is the same only if the area of the 
tablet in the Minivessel is appropriated scaled down with the liquid volume with respect 
that of the tablet in the USP 2.  This could be achieved in practice by using a single (small) 
tablet in the Minivessel and number of tablets in the USP 2 equal to the ratio 
VL-USP2/VL-Minivessel.  Therefore, similarity of dissolution profiles in the Minivessel and 
in the USP 2 is expected if non-disintegrating tablets are tested as just indicated here. 
If the tablet is of the disintegrating type, then the tablet should more or less rapidly 
form small granules once added to the vessel and the granules may or may not reside only 
in the lower portion of the vessel.  Therefore, similarity of dissolution profiles following 
this approach may not happen.  Nevertheless, at least during the initial phases of the 
dissolution process even these tablets can be expected to generate similar dissolution 
profiles if the above-mentioned protocol is used. 
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Consequently, the objective of this work was to study experimentally the 
dissolution profiles both the USP 2 and the Minivessel aiming at establishing a relationship 
between them.  Aspirin tablets were used for this purpose.  Initially, large 325-mg caplets 
were used in order to establish baselines.  Then smaller 81-mg aspiring tablets were tested 
following Wang et al’s (2017) approach, i.e., by stirring at the agitation speeds 
recommended in Table 2.1 and by using the appropriate different number of tablets in the 
two systems to compare MD/MT profiles that were expected to be similar, although coming 
from two different systems, and despite the fact that the tablets were of the disintegrating 
types. 
 
Figure 2.1 Approach proposed by Wang et al. (2017) to predict the agitation speed in a 
mini vessel resulting in the same mass transfer coefficient as in a USP 2 system operating 
at a given agitation speed.  The arrows point to the agitation speeds that should be used in 
the mini vessel to obtain tablet-liquid mass transfer coefficients that are the same as those 
for the USP 2 operating at 50, 75, and 100 rpm (from left to right), respectively. 
Source: Wang, B., Bredael, G. and Armenante, P. M.  (2017) Prediction of the Operating Conditions for 
Similarity of Dissolution Performance in a Mini Vessel and a USP 2 Dissolution Testing System Using 




















EXPERIMENTAL APPARATUS, MATERIALS AND METHOD  
 
In this work two different types of dissolution testing apparatuses were used.  They 
included the Standard USP-Dissolution Testing Apparatus 2, which will be referred to as 
the Standard System or USP 2, and the Minivessel-Minipaddle dissolution system, referred 
to as Minivessel.  
 
3.1 Experimental Test Apparatuses 
3.1.1 Standard Dissolution Vessel and Agitation System (USP 2) 
The Standard USP 2 system consisted of a Distek 5100 bathless dissolution system (Distek 
Inc., North Brunswick NJ), capable of using seven unbaffled cylindrical glass dissolution 
vessels. Each vessel had an internal diameter, T equivalent to 100.16 mm and an overall 
capacity of 1 Liter, and a hemispherical bottom (Figures 3.1 and 3.2).  
The agitation system consisted of a standard two-blade paddle impeller mounted 
on a shaft which was connected to a motor in the Distek system. Actual measurements 
were taken to determine the geometry of each component of the impeller using a caliper.  
The dimensions were as follows: shaft diameter was 9.53 mm, length of the top edge of the 
blade 74.10 mm; length of the bottom edge of the blade 42.00 mm; height of the blade19.00 
mm; thickness of the blade 5.00 mm. The distance between the lower edge of the impeller 




When 900 mL of dissolution media were added to the USP 2 vessel, the liquid 
height, H, measured from the bottom of the vessel, was 128.8 mm, and it was 82 mm when 
the vessel was filled with 500 ml of media.  
 
Table 3.1 Dimensions of impeller used in Standard USP 2 Dissolution System 
Component Dimension (mm) 
Shaft Diameter 9.53 
Length of Top Edge of Blade 74.10 
Bottom Edge of Blade 42.00 
Height of Blade  19.00 
Thickness of Blade 5.00 
 
Source: Armenante P. M, Wang: Experimental and Computational Determination of the Hydrodynamics of 










Figure 3.2 Distek Premier 5100 dissolution system used in this work.  
 
3.1.2 Minivessel System 
The Minivessel apparatus was one the most common commercially available minivessel 
systems. It consisted of a small cylindrical glass vessel with a hemispherical bottom and a 
working volume of 100 ml, provided with a mini paddle placed centrally in the vessel 
(Figure 3.3). The exact dimensions of the minivessel system under investigation are given 
in Table 3.2 and Figure 3.4. These dimensions were obtained by direct measurement of the 
minivessel provided by Merck Company, Rahway, New Jersey (courtesy of Gerald 
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Bredael) [6].  Since the temperature in Minivessel could not be appropriately maintained 
with the Distek Premier 5100, a different system was used, i.e., the Distek 2100B 
Dissolution System.  This system is similar to the Distek 5100 but is it provided with a 
Plexiglas bath in which the Minivessel was immersed in order to keep the temperature in 
the Minivessel constant.  The temperature in this system was maintained at the desired 
value by recirculating water from a thermostatic external recirculation apparatus (Digital 
Polystat Temperature Controller, Cole-Palmer Circulating System), as shown in Figure 3.5 and 3.6.  
 
   
Figure 3.3 (a) Minivessel dissolution apparatus including small volume vessel, minipaddle 













Figure 3.3 (b) mounting plate to adapt minivessel to standard opening for USP2 vessel in typical 
dissolutin testing system. 
            






Table 3 2 Dimensions of Mini Paddle 
 Dimension (mm) 
Shaft Diameter  6.40 
Length of Top Edge of Impeller Blade  27.58 
Length of Bottom Edge Impeller Blade  17.00 
Length of Impeller Blade  8.08 
Thickness of Impeller Blade 1.60 
 
Source: Armenante P. M, Wang: Experimental and Computational Determination of the Hydrodynamics of 
the Minivessel Dissolution Testing System 
 
 





Figure 3.6 Plexiglas water bath used in this work attached to Cole Palmer Circulating System  
(not shown). 
3.2 Experimental Materials 
Dissolution studies were conducted using 325-mg enteric-coated aspirin caplets (CVS 
Pharmacy) and 81-mg, round, enteric-coated aspirin tablets (Bayer Enteric Coated Aspirin) 
as the dissolving tablets. The dimensions of the tablets were measured using a caliper. The 
width, length, and thickness of the 325-mg caplet were found to be 4.1 mm, 9.3 mm, and 
4.0 mm, respectively.  The round 81-mg tablet had a 6.5-mm diameter and a 3.0-mm 
thickness. 
The dissolution medium for the 325-mg aspirin caplets consisted of a 0.05 M 
acetate buffer solution prepared by mixing 14.95 gram of sodium acetate trihydrate and 8.3 
ml of glacial acetic acid with distilled water to obtain to 1-Liter solution with a pH of 4.5 
+/- 0.05, as describes in the USP (32).  The dissolution medium for 81-mg aspirin tablet 
consisted of a solution of 0.1N hydrochloric acid and 0.20 M tribasic sodium phosphate, 
 
22 
which was adjusted when necessary with 2 N sodium hydroxide to a pH of 6.8+/-0.05, as 
specified in the USP (32). 
All media were degassed in the degassing apparatus shown in Figure 3.7 following 
the USP General test chapter on DISSOLUTION <711> based on the degassing method 
developed by Moore and Flanner, (1966) (2). The medium was placed in the Carboy tank 
which was then connected to a vacuum pump for 30 minutes, while all other valves in the 
system were closed. This stock solution was used in 100ml, 500ml and 900ml aliquots, as 
required by the experiments.  Stock solutions were used as needed, i.e.  500 ml and 900ml 
in experiments with the USP 2 system and 100 ml in the experiments using the  Minivessel 
dissolution testing apparatus.  
 




3.3 Experimental Methods 
Two testing methods were used to conduct the dissolution tests.  A summary of the 
Operating Conditions for Dissolution Experiments is reported in Table 3.3.  All 
experiments with both methods systems were conducted in nine replicates to determine 
reproducibility. 
3.3.1 Method 1-USP 2 
This experimental method was utilized with the USP 2. Although the Distek 5100 unit is 
equipped with seven standards stations, each one capable of receiving individual one-liter 
vessels, here only one vessel was used each time.  Dissolution studies were conducted with 
a 325-mg full dose of aspirin as well as with approximately half dose (after splitting a tablet 
in two). Additionally, tests were similarly run using 81-mg aspirin tablet, with 5 such 
tablets at the same time (i.e., 405 mg). 
Method 1 consisted of placing the vessel in the Distek 5100 dissolution unit, 
lowering the paddle impeller in the vessel, measuring key geometrical parameters (impeller 
clearance, impeller position), and adding the proper volume of medium.  The previously 
de-aerated medium was gently poured into the vessel to minimize the introduction of air.  
The dissolution medium temperature was raised to 37+/- 0.05degree centigrade and the 
system was allowed to equilibrate at this temperature prior to starting the experiments. The 
thermal inertia of the vessel caused the resulting temperature of the liquid to be 37 degrees 
centigrade. This medium was kept at 37 degrees centigrade throughout the dissolution 
experiment by the Distek 5100 temperature controller.   
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When the whole 325 mg tablet was used the volume of medium was 900 ml. When 
half caplet was used, 500-ml of medium was added.  In addition, experiments were 
conducted in the USP 2 using 81-mg tablet, 5x81-mg tablets were used at once.  In each 
experiment the tablet or the tablets (when using 5 at once) where was dropped into the 500 
ml of the medium in standard system vessels according to the USP (USP2008). Agitation 
speed was started as soon as the tablet(s) reached the bottom of the vessel.  In all USP 2 
experiments the agitation speed was kept constant, at either 50, 75 or 100 rpm, depending 
on the experiment.                       
 
 




3.3.2 Method 2-Minivessels 
Mini paddle experiments were run with half dose of the 325-mg aspirin that was used in 
the standard paddle apparatus. Single doses of 81 mg aspirin were used in the second set 
of tests.   Experiments were run at stirring speeds of 50 rpm,75rpm, 100rpm,125 rpm and 
150 rpm. 
This method was used with the minivessel.  The minivessel was mounted in the 
commercial Distek 2100 B Dissolution Testing System, using a round mounting plate with 
a central opening to accommodate the minivessel inside the round opening where the one-
liter vessel is typically placed during a dissolution test (Figure 3.9).  The mini impeller was 
similarly assembled on the same system by unscrewing the large apparatus 2 paddle and 
replacing it with the entire minipaddle impeller shaft instead.  The off-bottom impeller 
clearance used in this work, measured from the bottom of the paddle to the bottom of the 
vessel was 10 mm, which, when appropriately scaled, is very close to that of the standard 
USP 2 system.  This is the clearance commonly used in industry.  
In order to maintain the dissolution temperature of the medium constant at 37+/- 
0.5 degree centigrade, water was circulated the water bath in the Distek 2100 B system 
using the external Cole Palmer Circulating Bath (Figure 3.6) 
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Figure 3.9 Schematic of Minivessel system showing tablet position. 
 
The tablet was dropped into medium after the temperature of 37 degree centigrade 
was verified using a hand-held thermometer. When the tablet had reached the bottom of 
the vessel the agitation was started at the prescribed impeller speed. Experiments in the 
minivessel were conducted at 50, 75, 100, 125,150 rpm, as well as at 86.3, 109.7, and 129.2 
rpm (in order to verify the appropriateness or a previously developed dissolution model). 
 
3.3.3. Sample Collection and Analysis 
In both methods, the first sample was taken right after the agitation had started (defined as 
the zero-time).  Each experiment lasted 45 minutes. The samples were taken manually, at 
five-minute intervals during the 45-minute period.  Samples were taken with a 10-ml 
syringe (HSW) connected to a 2mm cannula. The volume of each sample was 10 ml for 
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the USP 2 experiments and 2.5 ml for the minivessel experiments. The volume of medium 
removed was not replaced in accordance to USP 2 procedure [2, 7,8,9]. 
The sampling location (where the tip of the cannula was) was midway between the 
impeller shaft and the vessel wall, horizontally, and midway between the top edge of the 
impeller and the surface of the dissolution medium vertically.  This is within the sampling 
zone prescribed by USP. A total of ten samples were taken in each experiment. 
The samples collected during the experiments with the 325-mg caplets were filtered 
through a Whatman filter paper #2 to remove possible solid particles that could enter the 
sample prior to analysis. The samples collected during all experiments with the 81-mg 
tablets were filtered with an in-line disposable Polypropylene 0.45 µm filters (Whatman 
Puradisc 25 PP) mounted at the end of the cannula, and later with an in-line 10 µm 
polypropylene filter (Distek) mounted in a small Teflon housing in the cannula. 
For all samples collected in the USP 2 experiments, the first 2 ml of the 10-ml 
sample were discarded, and the remaining 8 ml were filtered and transferred to a vial until 
analyzed.  The samples collected in the Minivessel experiments were filtered and used as 
such. 
Sample analysis to determine the aspirin concentration in the sample was carried 
out using a 1-cm quartz cell placed in an ultraviolet (UV) visible spectrophotometer (Cole-
Palmer S2100+ Series).  The absorbance of the drawn samples was measured at the 
specified wavelength of 265-nm for aspirin. The quartz cell was rinsed twice with the same 





Table 3.3 Operating Conditions for the Dissolution Experiments 
Dose 325mg (CVS Coated Aspirin) 
81mg (Bayer Enteric Coated Aspirin) 
Medium 500ml, 900 ml De-Aerated Acetate Buffer  
500ml, De-Aerate (0.1NHCL+Tribasic 
Phosphate Buffer.) 
100ml      De-Aerated Sodium Acetate Buffer  
100ml De-Aerated (0.1NHCL +Tribasic 
Phosphate Buffer) 
 
Temperature  37 Degrees Centigrade 
Agitation Speed USP2 -  50 rpm, 75rpm,100 rpm 
Mini vessel 50 rpm, 75 rpm 100 rpm,125 rpm 
150 rpm, and also 86.3, 109.7, and 129.2 rpm 
Filter Polypropylene 0.45 µm filters (Whatman 
Puradisc 25 PP) 
Whatman Filter Paper #2 
10 µm propylene filter (Distek) 
 
Ultraviolet Wavelength 265nm 
Sampling Time 5minute interval; Total 45minutes 
 
Calibration curves were generated from reference standard aspirin solutions (using 
the appropriate medium for each) for the 325-mg coated caplets and 81-mg enteric coated 
tablets, and diluting them with the appropriate aspirin dissolution medium to obtain 
solutions of known concentrations.  The absorbance of solutions of know aspirin 
concentrations was obtained to generate absorbance vs. concentration standard curves, as 
reported in Table 3.4 and Table 3.5.  The calibration curves were found to be linear in 
concentration ranges of interest here (R2=1 and R2=0.999, respectively).  The aspirin 
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concentration in a given sample was obtained by entering the absorbance value in the 
appropriate calibration curve. 
Table 3.4 Calibration Data for 325mg Aspirin Caplets 
Concentration (mg/ml) Absorbance 1(nm) Absorbance 2(nm) Average 
Absorbance(nm) 
0.146 0.499 0.451 0.450 
0.286 0.861 0.854 0.858 
0.429 1.288 1.289 1.289 
0.572 1.706 1.710 1.708 
0.715 2.130 2.126 2.128 
0.858 2.548 2.542 2.545 
1.00 2.968 2.965 2.967 
 
  




Table 3.5 Calibration Data 8 mg Aspirin Tablets  
Concentration 
(mg/ml) 
Absorbance1 (nm) Absorbance 2(nm) Average Absorbance 
(nm) 
0.0081 0.089 0.088 0.089 
0.0162 0.116 0.117 0.117 
0.0243 0.139 0.138 0.139 
0.0324 0.166 0.166 0.166 
0.0495 0.192 0.192 0.192 
0.0486 0.214 0.215 0.215 
0.0567 0.236 0.235 0.236 
0.0648 0.265 0.264 0.265 
 
 




3.4 Data Analysis 
3.4.1  Calculation of the Fractional Drug Mass Released During Dissolution from 
Experimental Data 
The drug concentrations were used to calculate the total mass of drug released in the 
medium during the experiments.  In this work, the dissolution profile is represented as a 
cumulative percentage of the amount of drug released at each sampling time. The amounts 
of drug released at each time are presented in terms of drug release fraction, MD/MT, i.e., 
the mass of released drug in the dissolution medium at any time t divided by the total mass 
of the drug initially in the tablet. 
The absorbance data were obtained from the spectrophotometric analysis. Then the 
method described below utilizes the concentration of aspirin in the dissolution medium at 
any given time (Cj in mg/mL), and then transforms it into fraction of drug mass released 
from the tablet (MD/MT) using the equations 3.1 and 3.2 to account for the drug mass 
removed with each sample, [18]. 
                                                                                                               (3.1)
                                                                               (3.2) 
 
where j is an index identifying the sample number (j=1, 2, . . . .10); mD (t j) is the mass of 
released salicylic acid at time tj; mT is the total mass of the salicylic acid initially in the 
 
32 
tablet; CJ is the dissolved aspirin concentration in the jth   sample; C* is the concentration 
of the aspirin when the tablet is fully dissolved in a specific dissolution volume (500ml or 
900ml for the USP2 and 100ml in the minivessel).  ∆V is the sampling volume (10ml or 
2.5 ml), V is the initial volume of dissolution, (500ml,900 ml, or 100ml).  At the beginning 
of the experiment when (t=t1=0) minutes, the first sample was taken immediately at (j=1) 
resulting in a concentration C1. 
The dissolution profiles obtained from dissolving the tablet in the standard 
dissolution apparatus and the minivessel setup were compared to determine whether these 
dissolution curves were statistically similar or not.  A model-independent approach that 
produces a single value from a dissolution profile providing direct comparison of the 
dissolution data was employed.  Consequently, the results do not depend on the choice of 
specific parameters for fitting data, but on the chosen sampling time ti, (i=1 n) in the 
calculation. Model independent approaches include ratio tests and fit factors, [5,9,10].  
The fit factor approach is that recommended by the FDA to quantify the 
similarity/difference of the two dissolution profiles. This approach includes a difference 
factor f1 and a similarity factor f2. The difference factor f1 calculates the percentage 
difference between the two curves at each point and measures the percentage error between 
them over all time points, which is given by equation 3.3. 
                                                                                                                             (3.3) 
where Ri is the reference assay time t and Tt is the test assay at the same time, and n is the 
number of points respectively at each sample point, j. The higher f1 (which can be in the 
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range of 0 to 100), the higher the average difference between the reference and test curve 
is [9,10]. 
The similarity factor f2 (9,10) is a logarithmic reciprocal square root transformation 
of the sum of squared errors of differences between the test and product dissolution profiles 
over all time points and is a measurement of the similarity between the two test methods 
by comparing the drug release profile as shpwn in equation 3.4. 
                                                                                      (3.4) 
where n is the number of sampling points, Σ is the summation of all time points and Rt and 
Tt are the cumulative percentage dissolved at each of the selected time point of the 
reference and test product respectively. When two profiles are identical f2 =100, and with 
an average difference of 10 percent at all measured time the result is a f2 value of 50. 
The higher the f2 value (which can be in the range - ∞ to 100), the lower the average 
difference between the reference and the test curve is, [5]. Public Standards have been set 
by the Food and Drug Administration, (FDA) for f1 and f2   factors. Accordingly, statistical 
similarity between the two curves being compared requires that 0<f1<15, and 50 <f2<100 
[4-5,9]. 
In general, comparison of dissolution profile is intended to compare the results of 
different batches of product to ensure batch-to-batch conformity, product quality after 
scaling up or post approval changes (SUPAC) or company release rates for different 
strength of products for biowaiver purposes. However, the principle can be applied any 
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time a profile comparison is needed [12,15].  During the last decade f2 calculation has been 
a recommended method in several FDA Guidance [12,14-15].  
3.4.2 Determination of the Tablet-Medium Mass transfer Coefficient from 
Experimental Dissolution Data 
For a dissolution process in which a non-disintegrating tablet slowly erodes as a result of 
dissolution, it is possible to extract the tablet-liquid mass transfer coefficient from the 
experimental dissolution data. This is achievable by rearranging, and integrating the basic 
mass transfer equation. The dissolution of chemical species from the surfaces of a tablet 
into the adjacent fluid such as dissolution medium can be expressed as [24]: 
                                                             dC/dt= kA/VL(Cs-C)                                                       (3.5) 
where C is the drug concentration in the dissolution medium, Cs is the solubility 
concentration of the drug, k is the mass transfer coefficient, A is the tablet surface area 
exposed to the dissolution medium, and VL is the liquid volume, and is liquid bulk is 
assumed to be well mixed. The primary objective is to determine the mass transfer 
coefficient k using the experimental data: 
                                                                k= VL/A(CS-C) dC/dt                                      ( 3.6) 
As time progresses and the tablet erodes, the surface area is reduced. The tablet 
under investigation has a defined height-to-diameter ratio β.  Even though it is circular as 
it erodes it can be assumed that it will maintain this height to diameter ratio during the 
dissolution process. This assumption is considered as reasonable if the mass transfer 
coefficient is similar on all exposed sides.  Then A can be calculated by knowing the ratio 
                                                                     β = ht/dt                                                                    (3.7) 
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where ht and dt are the height and diameter respectively of the tablet.  For the case of the 
81mg aspirin ht and dt were 3mm and 6.5mm, respectively, giving a β value of 0.462. If 
only the top and side surface of the are exposed to the dissolution medium, the interfacial 
area available for mass transfer can be expressed as 
                            A= 𝜋𝜋d2T (1+4β)                                                                             (3.8) 
                                                 4 
From a mass balance for the drug disappearing from the tablet and appearing in the 
dissolution medium it must be at any time that: 
                     C    =     ρ𝑇𝑇 (VTO - VT) + C0                                                                      (3.9) 
                                              VL                                                                                            
Where ρT VTO and VT are, respectively, the density, initial volume and volume at time t of 
the tablet, and Co is the initial concentration of the drug in the dissolute   ion medium (which 
is zero in this work). The volume of the tablet is given by: 
                                                    VT = hT   πd2T       =     β πd3T 
                                                                                                      4           4                                        (3.10) 
When this equation is substituted in equation 7, one can obtain the tablet diameter as the 
tablet dissolves and C increases:   
                                                 dT   = [d3TO -  4 (C-CO) VL    ]1/3 
                                                                        πβρT                                                                        (3.11)                                                
Substituting this equation into equation 6 gives an expression for A as a function of C:                                                                                        
                                                  A(C) = π [d3TO – 4(C-C0) VL]2/3 (1+4β) 
                                                                                   πβρ𝑇𝑇      4                                (3.12) 
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An estimation of the mass transfer coefficient k, assumed to be independent of time 
and varying tablet volume, can be obtained by substituting this expression for A in equation 
4 and integrating it. The result is: 
                                            (3.13)  
where Ct is the drug concentration in the dissolution medium at time t. Since experimental 
data of Cc versus t are available this equation can be used to calculate k by numerical 






4.1 Results for In-Vitro Dissolution Tests with 325-mg Coated Aspirin Caplet 
and with Half Caplets 
The results for the dissolution tests conducted using Method #1 (USP2 or Standard 
Dissolution System) and Method # 2 (Minivessel Dissolution System) when both the 325-
mg tablet were used are presented in this section. To check whether the drug release rate 
for the test formulation was influenced by different stirring speeds, dissolution profiles 
were generated using both the USP 2 and the minivessel dissolution systems.  
The dissolution profiles for the 325-mg full dose aspirin caplets are presented in 
figure 4.1 for the USP   Figures 4.2 also demonstrate the dissolution profile for the half 
dose 325mg aspirin at the agitations speeds of 75 and 100rpm both at an operating volume 
of 500 ml and 4.3 for the Minivessel for the case in which only half caplet was used.  The 
results are presented in terms of (MD/MT), the ratio of the mass of drugs in solution at any 
time relative to the total initial amount of drug in the tablet, obtained with the 325mg caplet 
in both the USP 2 in case and with half caplet for the minivessel case. These figures show 
how the dissolution profiles vary with agitation speed.  In the standard system, all curves 
began at the same initial mass ratio (MD/MT = 0) but then independently diverged with 
time, displaying an increasing release rate with time, as one would expect.  
The dissolution profile for full dose 325mg tablet in Figure 4.1 showed 3 different 
drug release steps. The initial step occurred between 0-5 minutes, where the largest amount. 
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of drug was release, approximately 80%. Between 5and 15 minutes another 20%was 
released, the system approached saturation thereafter and plateaued. 
Examination Figure 4.2. with the curves for the half dose, 50 rpm curve showed 
that the drug release at 5 minutes was MD/MT=48%.  There was a gradual increase in the 
amount of drug released up to the 35-minute mark.  The curve then plateaued at 
MD/MT=97% for the final 15 minutes.  The curve for the half dose 100- rpm showed the 
most significant release rate: at 5 minutes MD/MT =90% and the amount of drug released 
increased to MD/MT=115% at 10 minutes and then fluctuated for the next 20 minutes and 
then settled to MD/MT =110% This value was indicative of 4.066 standard deviation from 
the average weight used in analysis. 
The release rates at the agitation speeds remained distinct throughout the 
dissolution process. In addition, the f1 and f2 values quantifying the significant difference 
or similarity/between the dissolution curves can be seen in Table 4. 1..  In this table the 
baseline was the 100 rpm value.  Clearly, visual observation showed that the profiles 
exhibit different release rate, higher agitation rate guaranteed higher release, and consistent 
results were obtainable with half dose in this regime. 
The dissolution profiles for the 325mg aspirin using half caplet in the minivessel 
are presented in Figure 4. 3.. There is a significant similarity between the dissolution profile 
for the tablet dissolved at 100 rpm, 125 rpm, and 150 rpm. These curves are however 
different from those representing dissolution obtained at the lower agitation speeds of 50 
rpm and 75 rpm, which remained distinct and separate throughout the dissolution process. 
As before, all five curves began at MD/MT=0, but diverged with time.  At 5 minutes the 
dissolved fraction for the three upper impeller speeds increased nearly simultaneously to 
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MD/MT = 45% and then at 10 minutes they had an identical value (MD/MT =62%).  Then 
the curves coalesced, plateaued and stay at that value from 10 to 45 minutes since the 
solution had then reached saturation, given the large amount of drug and the small liquid 
volume. 
The release rates of the 50 rpm, and 75 rpm were much slower, and at 5 minutes 
they were at MD/MT =10%, and MD/MT=20%, respectively.  These curves stayed distinct 
and separate throughout the dissolution process and plateaued at 30 minutes at values of 
MD/MT=45% and MD/MT= 55% respectively.   
For each agitation speed, the corresponding f1and f2 values of replicated experiment, shown 
in Table 4.3., quantified the similarity/difference and showed good agreement (f2>50, and 
f1<15 as per FDA recommendations [5,10]). 
Figure 4.4. compares the dissolution profile from both systems.  Clearly, there is 
no similarity seen among the curves in both systems. This demonstrates the unsuitability 
of minivessel to replicate the drug release process for dosage forms that are routinely used 
in the USP 2 and are not of low dosage. Saturation was approached as early as 15 minutes 
in the minivessel operating at the higher agitation speeds, and corresponded to an MD/MT 
ratio of about 60%.  
No coning was seen in the minivessel or the standard system for the full dose and 
half dose 325 mg aspirin at any agitation speed.  The experiment results were always within 





Figure 4.1 Dissolution profiles for Full Dose 325mg Aspirin at a agitation speeds of 











Figure 4.3 Dissolution profiles for 325mg Aspirin Half Dose at mixing speeds, (50- rpm, 




Figure 4.4 Dissolution profiles for Half Dose 325 mg Aspirin in USP 2(VL=500ml) and 




Table 4.1 f1 and f2 values for dissolution profiles of 325mg Aspirin Caplet-Half Dose in 
the USP 2 at different mixing speeds  
 
 
Table 4.2 f1 and f2 values for dissolution profiles of 325mg Aspirin Caplet-Half Dose in 
minivessel system at different agitation speeds. The 100-rpm was used as the baseline value 
 
Impeller Speed (rpm) Dosage Run Number Difference Factor 
f1 
Similarity Factor f2 
50 Half Dose 1 - - 
  2 8.181 67.910 
  3 13.910 78.460 
75 Half Dose 1 - - 
  2 1.5426 90.961 
  3 6.5187 75.962 
100 Half Dose 1 - - 
  2 2.5887 82.052 
  3 4.4011 75.962 
125 Half Dose 1 - - 
  2 3.834 74.910 
  3 6.1468 65.292 
150 Half Dose 1 - - 
  2 1.6052 84.432 
  3 2.701 85.618 
Rotational Speed (rpm) Dosage Run Number Difference Factor f1 Similarity Factor f2 
50 Half Dose 1 - - 
  2 7.583 61.279 
  3 9.247 55.519 
100 Half Dose 1 - - 
  2 3.125 74.608 
  3 8.1239 53.563 
100 Full Dose 1   
  2 3.125 74.608 




4.2 Results for Invitro-Dissolution Test For 81-mg Enteric Coated 
Aspirin 
The Results for the Dissolution Test conducted with the 81-mg tablets using Method #1, 
(Standard Dissolution System) and Method # 2 (Minivessel Dissolution System) are 
presented in this section. To check whether the drug release rate for the test formulation 
was influenced by different stirring speeds, dissolution profiles were generated with the 
standard system and the minivessel dissolution system. The dissolution profiles of  aspirin 
tablet are presented in Figures 4.5 and 4.6. for the USP 2 and FiguresS 4.7 and 4.8 for the 
Minivessel. A  comparison of the dissolution rates in both systems are shown in Figures 
4.9 to  4.14.  The results are presented in terms of (MD/MT), the ratio of the amount of drugs 
in solution at a generic time relative to the total initial amount of drug in the tablet, obtained 
when the 81-mg tablet is completely dissolved. These figures show that the dissolution 
profiles vary with different mixing speeds.  
4.2.1 Dissolution Results for the USP 2 Using a Single 81-mg Aspirin Tablet and 5 
Doses of the 81-mg Aspirin Tablets 
The dissolution curves in Figure 4.5 describes the dissolution profiles with a single 81-mg 
aspirin tablet at an agitation speed of 100  rpm, operating at a volume of 500-ml (as 
specified in the USP). while Figure 4.6. shows the dissolution profiles with 5x81-mg 
aspirin tablets at 50 rpm, 75 rpm and 100 rpm, also operating at volume of 500ml. 
The 100rpm single dose profile showed  three distinct stages of drug release a 80 
% dissolution release  was observed during the initial step at 20 minutes,during the second 
stage MD/MT=25% ,more of the drug was dissolved to produce adissolution of 105% where 
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the curve plateaued .This curve showed the most vigorous dissolution rate but the least 
reproducable results.  
The curves in Figure 4.6. show similar values up to 5 minutes, but then diverge 
thereafter ..They differed  in both shape and profile , requiring different times to plateau.All 
curves in Figure 4.6.  showed distinct stages in their release rate.  During the first 5 minutes 
the 5-dose, 100- rpm standard curve showed a release amount of MD/MT=10%. The greatest 
percentage of the drug dissolved in the shortest time was at 100 rpm, with 5 doses 
(MD/MT=50%) and it occurred between 5 and 10 minutes to reach 60% dissolution; 19% 
more drug dissolved at t=15 minutes to reaching MD/MT=79%.  At 20 minutes the 
dissolution rate was MD/MT=85% the curve then plateued at 94% at 45 minutes.The 75-
rpm, 5-dose profile showed the highest amount of drug release between 5and 10 minutes 
and between 10 and 15 minutes .Dissolution during these two steps were MD/MT=27% and 
MD/MT=23% respectively. The drug released progessively increased to 80% at 30 minutes 
then the curve increased slightly ,remained constant at 35, and 40 minutes and increased 
slightly at 45 minutes.  
As for the 5-dose 50-rpm dissolution curve, at 5 minutes the dissolution amount 
was MD/MT =5% and increased gradually up to MD/MT=70% at 45 minutes.  This release 
rate did not comply with the dissolution specification stated in the USP that after 45 
minutes MD/MT=85% of the drug should be released ,the other profiles suggested a greater 
compliance [3,4].   
The standard deviations among replicate curves were low with a maximum value 
ranging from a maximum of 2.73 to a minimum of 0.93.  The results for the f2 values in 
Table 4.2.0 show that the curves at any given sagitation speed are reproducible. Coning 
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was observed during the dissolution of the 5-dose, 50-rpm tablets, and the 5-dose 75-rpm 
tablets, but was not observed at 100 rpm.   
 
4.2.2 Dissolution Results for the Minivessel Using a Single 81-mg Aspirin 
Tablet 
Figures 4.7 and  4..8  show the averaged dissolution profile for a single 81-mg aspirin in 
the minivessel  at different agitation speeds.  Figures 4.9. to 4.14. compare the dissolution 
profiles of 81mg aspirin in both the standard USP2 and the Minivessel.  Examination of 
Figures 4.7 and 4.8. showed that the initial dissolution started at MD/MT=0 for all curves 
and became  increasingly distinct as they reached the 5 minute mark . Here they diverged 
with time depending on the agitation speed. The curves descibing the dissolution at 125 
rpm and 150 rpm remained close and became undistinguishable at 25 minutes. The 100 
rpm curve showed a similar profile but a slower dissolution rate. 
The 50 rpm and 75 rpm curves converged up to t=10 minutes where the amout was 
identical at MD/MT=30%. The curves then diverged into two separate profiles with slightly 
similar shape but different drug release rate. The curves showed a consistent 10% 
difference between them as the gradually progressed up to 30 minutes when they plateaued  
at 55% and 65% respectively.   
The curves for the 125 rpm and 150 rpm agitataion speeds showed three stages  in 
their release rate.The greatest percentage of drug dissolved occurred in the second step 
between 5and 10 minutes at agitataion  speeds of 125 rpm and 150 rpm. Approximately 
55%, and 60 % of the drug were dissolved in 5 minutes, respectively. The 150-rpm profile 
 
46 
showed that between 10 and 15minutes 15% more of the drug dissolved, bringing the total 
percentage of drug dissolved at this time to around 80% and remaining at this value for the 
next 5minute up to the 20 minute mark. There was a further increase by approximately 
18% to reach 98 %,where the curve plateued.  At 125-rpm agitataion speed the curve 
reached the 80% drug release at 30 minutes, fluctuated below this value at 35 minutes but 
re-emeged at this 80% value at 40 to 45 minutes.  Table 4.3 shows consistent simularity 
between replicated  experiments at each speed. 
Figure 4.9. shows the profiles for the USP 2 system with 500ml at 50 rpm using 
five doses of 81mg aspirin tablets and the results for the minivessel at agitation speeds of 
50 rpm and 75 rpm and the predicted speed of 86.3 rpm.  The profiles at both impeller 
speeds of 75 rpm,and 50 rpm in the minivessel showed a somwhat similar profile to the 50 
rpm 5-dose in the USP 2.  However, the 86.3 rpm profile with minivessel showed a greater 
similarity to the 5-dose 50 rpm provile in the USP 2, as also evidenced by the f1 and f2 
values in Table 4.4.. Coning was observed in the minivesselat at 50 rpm and at both 50rpm 
and 75 rpm in the standard system.  
Figure 4.10. shows that the profile for the 5-dose, 75-rpm, 500-ml in the USP 2 
were similar to those at agitation speeds of 100 rpm and 109.7 rpm in the minvessel system, 
but not similar at 75 rpm in the minivessel.  This was particulary evident in the early stages 
of dissolution between 0 and 25 minutes.  Coning was observed at 75rpm in the USP 2. 
Figure 4.11. demonstrated the ability of the minivessel operating at 125 rpm,150 
rpm to produce a drug release profile similar to the 5-dose 100-rpm, 500-ml in the USP 2.  
The 125 rpm curve however showed an even closer relationship. The 100 rpm curve, from 
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the minivessels was also observed to generated a similar profile to the 125rpm curve, but 
with a lower drug release than in the other curves. 
Figure 4.12. presents the profiles for the 5-dose, 100-rpm case in the standard 
system and the profile produce in the minivessel system operating at athe motion speeds 
of 125 rpm,129.2 rpm,and 150 rpm. The profiles are all very similar.   
Figure 4.13 and 4.14. show a comparison between the dissolution profiles for 5-
dose 81-mg aspirin tablets in the USP 2 at different standard agitations speeds (50, 75, and 
100 rpm) and the corresponding profiles for a single-dose 81-mg aspirin tablet in the 
minivessel at the agitation speeds that were predicted by Wang et al. (2017) to generate 
similar mass transfer coefficients (86.3, 109.7 and 129.2 rpm, respectively).  The profiles 
appear to be similar, which implies that the Wang et al. approach to operated the two 
systems, based on a similarity of the the A/VL ratio and k values between the USP 2 and the 
minivessel, appears to be correct.  This is further confirmed by the results shown in Table 
4.5. indicating that the f1 and f2 values comparing the USP 2 profiles with the minivessel 
profiles at the prescribed agitation speeds are almost alwasys the most appropropriate 
values for profile similarities.  This appears to be so even although the predictions by Wang 
et al. were obtained for a non-disintegrating tablet. 
The calculated f2 values in  Table 4.5 are in good agreement with these 
observations.  Drug release profile with f2>50 were obtained at all  stirring rates in the 
minivessel.  However, a higher f2 value was obtained for 129.2  rpm which is closest to 
that of the 100-rpm 5 dose in the standard system. The average standard deviation was 
observed to be consistent with the f2 values ran  Similarly, the f2 values showed a consistent 
relationship between the predicted value of 86.3rpm in the minivesseland the 50rpm 5 dose 
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in the standard system. There was howver a slight deviation with the predicted value of 
109.7 rpm in the minivesseland the 75 rpm 5-dose curve obtained in the standard system 
as the 100rpm in the minivessel resulted in acloser visual relationship as wellas a a higher 
f2 correlated value. 
4.2.3  Experimental Determination of the Tablet-Medium Mass Transfer Coefficient 
from Dissolution Data for 81-mg Aspirin Tablets 
The average  experimental dissolution data,from 0 to 45 minutes ,the properties  of 81 mg 
aspirin tablet and the dissolution sytem were used as an input in equation 3.13 to obtain the 
average tablet-medium dissolution mass transfer coefficients k, through numerical 
integration of equation 3.13 
Studying compartively the dissolution process of 81-mg aspirin at different motion 
speeds  in both the standard USP2 paddle dissolution system and the minivessel system  it 
is observed from Table  4.2.3 and 4.2.4  that the mass tranfer coeffient intensified as the 
stirring rate increase and seem to be  impacted by the power volume relationship of the 
vessel. This is result is supported by earlier works [ 9].  
The mass tranfer coeffient values in the standard system increased with increasing 
agitataion speeds as well as the surface available. These values  were one order of 
magnitude smaller than that derived in the minvessel system except for the 50 rpm . It was 
observed that as the agitataiom speed increased there was a consistent  difference in the 
mass tranfer coeffient values  which increased correspondingly with agitataion speed . The 
mass transfer coefficient in the minivessel were for the respective agitataion speeds of 50 
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rpm,75 rpm,86.3 rpm,100 rpm,109.7 rpm,125 rpm ,129.2 rpm and 150 rpm and is shown 
in Table 4.2.4  .  
The correspondingly percentge  difference for these speeds when compared to the 
standard 100rpm 5 dose in the standard system.It is shown to be proportionate in the 
folowing order 80%,83%,84%,86%, 86.8%, 86.9%, 87.3% and 87.4% larger than the  mass 





Figure 4.5 Dissolution profiles for single-dose 81-mg aspirin tablet at  100 rpm impeller speed 




Figure 4.6.  Dissolution profiles for 5-dose 81-mg aspirin tablets at two different impeller 






Figure 4.7 Dissolution profiles for single-dose 81-mg aspirin at different agitation speeds, 




Figure 4.8 Dissolution profiles for single-dose 81-mg Aspirin at different agitation speeds, 




Figure 4.9 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 at 50 rpm and for a 






Figure 4.10 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 at 75 
rpm(VL=500ml) and for a single-dose 81-mg aspirin tablet in the Minivessel (VL=100ml) 
agitation speeds (75.100,109.7Rpm. 
 
 
Figure 4.11 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 at 100 rpm 








Figure 4.12 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 (VL=500ml) 
at 100 rpm and for a single-dose 81-mg aspirin tablet in the Minivessel at different agitation 
speeds. (125,129.2,150 Rpm). 
 
 
Figure 4.13 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 at different 
standard agitations speeds (50 and 75 rpm), VL=500ml and for a single-dose 81-mg aspirin 
tablet in the Minivessel at the corresponding predicted agitation speeds (109.7 rpm and 






Figure 4.14 Dissolution profiles for 5-dose 81-mg aspirin tablets in the USP 2 at different 
standard agitations speeds (75, and 100 rpm), VL=500ml and for a single-dose 81-mg 
aspirin tablet in the Minivessel at the corresponding predicted agitation speeds (86.3and 
109.7rpm) VL=100ml for mass transfer coefficient similarity.    
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Table 4.3 f1 and f2 values for dissolution profiles of 81 mg Aspirin Tablet in Standard 















50 Single 1 - -   
 Single 2 6.03132 59.2135   
 Single 3 10.119 51.6933 4.64281 65.8195 
       
50 5 Doses 1 - -   
 5 Doses 2 5.6545 74.8906   
 5 Doses 3 8.9853 66.3745 5.5753 76.2044 
       
75 5 Doses 1 - -   
 5 Doses 2 2.9353 3.2933   
 5 Doses 3 77.488 79.813 2.3893 84.26 
       
100 5 Doses 1 - -   
 5 Doses 2 2.3646 82.775 1.9346 82.826 





Table 4.4 f1 and f2 values for dissolution profiles of 81 mg Aspirin Tablet in Minivessel 

















50 Single 1 - -   
 Single 2 7.6578 68.2967   
 Single 3 6.0502 72.0413 6.0502 72.638 
75 Single 1 - -   
 Single 2 5.2741 71.686   
 Single 3 4.9439 73.4827 2.4903 72.4846 
83.6 Single 1 - -   
 Single 2 7.3945 69.8169 2.90488 86.839 
 Single 3 2.2486 89.8026   
100 Single 1 - -   
 Single 2 7.6598 68.2967   
 Single 3 5.9756 72.0413 3.25399 73.4969 
109.7 Single 1 -    
 Single 2 4.1473 73.557   
 Single 3 4.9660 73.211 1.4948 91.0094 
125 Single 1 - -   
 Single 2 2.7432 77.4877   
 Single 3 3.4548 84.6141 1.95807 84.6141 
129.2 Single 1 - -   
 Single 2 4.4182 65.2391   
 Single 3 2.8170 70.9521 2.2555 75.4969 
150 Single 1 - -   
 Single 2 3.9649 72.6918   
 Single 3 4.5565 68.8592 2.3877 81.3763 





Table 4.5 Comparison of f1 and f2 values for dissolution profiles of 5-dose 81-mg Aspirin 



















50 rpm USP 2 500ml 5 Doses 5.5733 76.2044  
50 rpm Minivessel 100ml Single 
Dose 
16.05 52.86 3.41 
75 rpm  Minivessel 100ml Single 
dose 
18.18 52.36 5.96 
86.3 rpm Minivessel 100ml Single 
Dose 
12.39 59.96 1.06 
       
75 rpm USP 2 500ml 5 Doses 2.3893 76.2044  
75 rpm Minivessel 100 ml Single 
Dose 
20.67 43.35 3.410 
100 rpm Minivessel 100ml Single 
Dose 
5.508 71.65 1.760 
109.7 rpm Minivessel 100ml Single 
Dose 
7.126 64.86 2.320 
       
100 rpm USP 2 500ml 5 Doses 1.9346 82.826  
100 rpm Minivessel 100ml Single 
Dose 
16.0631 44.7086 2.6108 
125 Minivessel 100ml Single 
Dose 
2.3937 81.0636 2.042 
129.2 Minivessel 100ml Single 
Dose 
2.6849 81.9899 1.534 
150 Minivessel 100ml Single 
Dose 







Table 4.6 Properties of 81mg Enteric Coated Aspirin and Dissolution System 
Properties  
Cs 3.14 kg/m3 
ρT 1350 kg/m3 
VL (Minivessel) 1*10-4 
VL (USP2) 500*10-4m3/9.00*10-4m3 
dTO   5Dose 0.035m 
dTO Single Dose 6.5*10-3m 
Β 0.462 
 
Table 4. 7 Mass Transfer Coefficients for 81mg Aspirin at different Mixing Speeds 
Calculated from Experimental Dissolution in standard System 
Impeller Speed (rpm) Dosage Mass Transfer Coefficient from Experimental 
Dissolution data kexp (ms-1) 
50 Single Dose 1.20*10-3 
50 5Dose 1.56*10-3 
75 5Dose  1.60*10-3 
100(500ml) 5Dose 1.70*10-3 
 
Table 4. 8 Mass Transfer Coefficients for 81mg Aspirin at different Mixing Speeds 
Calculated from Experimental Dissolution in Minivessel System 
Impeller Speed rpm Dosage Mass Transfer Coefficient from Experimental 
Dissolution Data kexp (ms-1) 
50 Single Dose 8.77*10-3 
75 Single Dose 1.02*10-2 
86.3 Single Dose 1.10*10-2 
100 Single Dose 1.23*10-2 
109.7 Single Dose 1.29*10-2 
125 Single Dose 1.30*10-2 
129.2 Single Dose 1.34*10-2 







An overall comparison between results from the Standard USP 2 paddle dissolution system 
and the non-compendial Minivessel dissolution apparatus shows that, in general, there is 
an apparent agreement between the experimental results and the predictions obtained with 
the Model Independent Approach of Fit Factors recommended by the FDA guidelines for 
the industry, for the comparison of dissolution profiles, [5,9] 
The dissolution profile from the predicted speeds of 50, 75, 100 rpm, running with 
5dose in the standard system and the 86.3,109.9, and 129.2 rpm running at single dose for 
81mg enteric coated aspirin was alternately selected as the reference profiles in this study.  
The aim of these series of test was to establish the relationship between the 
reference one-liter vessel and the small vessel assembly, comprising a small vessel and a 
minipaddle. 
The experimental dissolution data for the 81mg aspirin rather than the 325-mg 
aspirin indicated that using Minivessel with a higher impeller speed as determined by the 
fit factor and equations was more insightful to deduce an accurate result. These results 
appear to give a very decisive similarity dissolution rate for the 81mg aspirin single dose 
with the 100- rpm, 5dose according to the USP2 monograph to that of a single unit at 125 
rpm and 129.2 rpm in the Minivessel. The 129.2 rpm showed a slightly higher f2 value This 
is in good agreement with the earlier results [17] . 
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The alternate speeds of 50 rpm and 75rpm in the standard system, produced profiles 
which were comparable to those derived in the Minivessel at 86.3, and 109.7rpm in the 
Minivessel. There similarity was not as distinctive as those obtained at the higher speeds. 
It was expected that placing multiple dosages in one single vessel would form a 
cone of in- soluble excipients on the bottom of the vessel, that would further decrease the 
rate of dissolution. this did not occur at the 100 rpm motion speed, 5 dose or single dose, 
but at the 50 rpm 5dose, and 75 rpm 5 dose run. This agrees with unprecedent work in 
literature [17]. 
Coning effect during drug release would result in a decrease in the dissolution rate, 
and concentration of these products, such coning effects are confined to formulations with 
high amounts of insoluble excipients such as disintegrating tablets which form a 
disintegrated mass at the bottom of the vessel. Coning effect at low speed had the highest 
impact on drug release. 
The statistical similarity obtained in this work for the different motion speeds in 
both the standard systems and the Minivessel system respectively can be quantified by 
examining the values of the similarity/difference factors f1, and f2 in tables 4.1- 4.2 for the 
325mg, and tables 4.3 and 4.4 for the Minivessel. Table 4.5. compares the profiles in both 
systems  
In both vessels all the agitation speeds produced results which were within the range 
set up for FDA, similarity. When the profiles of the motion speeds in the Minivessel 
systems, and the standard system was compared it was seen that a consistent similarity 
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existed among the profiles of the higher motion speeds and the 5 doses 100 rpm 500ml, 
with 129.2 rpm in the Minivessel exhibiting the highest similarity value.  
The higher impeller speeds resulted in a better dispersion of the disintegrated 
particles and therefore a more significant dissolution profile [12]. 
The 75-rpm motion speed in the Minivessel showed values that were out of range 
with the stipulated FDA f2, and f1 values when compared to the 75 rpm curve in the standard 
system. The 109.7 rpm motion speed in the Minivessel system, however presented f2, and 
f1 values that made the profile produced claimed similarity to that of 75 rpm in the standard 
system. At the lower speed regimes, both 50 rpm, and 75 rpm motion speeds in the 
Produced at 50 rpm in the standard system. Even though the f2 values were in range the f1 
values were out of range, the 86.3 rpm however presented values that made the profile 
produced similar.  
The similarity factor f2 is found to be more sensitive in finding dis-similarity 
between dissolution curves than the difference factor f1. The values of the fit factors are 
dependent on the number of sampling time points chosen [5].  
According to the FDA guidelines, f1 values up to15 and f2 values greater than 50 
should ensure equivalence of dissolution curves, showing an average difference of no more 
than 10% at the sample time points. Based on these guidelines the 125 rpm, and 129.2rpm, 
and 150 rpm curves in the Minivessel and the 5dose 100 rpm curve for the 81m aspirin 
tablets show dissolution curve equivalence [10,18]. 
When using both the standard dissolution system, and the Minivessel system at an 
identical agitation speed, the small volume vessel showed a lower percentage drug 
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dissolution than the one-liter system for all the chosen impeller speeds for both the 325-
mg aspirin and the 81mg aspirin.  
When a comparison of the dissolution rate of the half caplet ,325mg aspirin and 
that of the 81-mg aspirin in the Minivessel was done, it was seen that a higher drug release 
was achieved for the single unit 81mg aspirin that the half caplet of the 325mg aspirin. 
Saturation for the half caplet 325 mg aspirin was reached as early as 15 minutes for the 
agitation speeds of 100 rpm,125 rpm and 150 rpm, and 25 minutes for the lower speeds of 
50 rpm and 75 rpm. These trends can be seen in Figures 4.2. 4.3, and 4.4 for the 325-mg 
aspirin and figure 4.7 ,4.8. for the 81mg aspirin where saturation sets in at 35 minutes. 
This outcome could be attributed to the size and shape of the dosage forms that also 
impact drug release. This shows that the Minivessel should preferable be used for powders, 
multi-particulate dosage forms and small tablets where the paddle apparatus would be the 
usual method of choice [13]. 
These investigations clearly showed that using small vessel setup, at equivalent or 
higher speeds are necessary to obtain similar dissolution rate in the standard USP 2 one-
liter vessel. When compared to the one-liter vessel, a speed factor of 1.29 have been seen 
to be a suitable prediction in the case of 81mg aspirin. 
The variation of the total mass transfer coefficient was studied experimentally for 
the 81mg aspirin. These studies were made in the same conditions with those presented for 
earlier determination of dissolution curve equivalence. The difference in the curve and the 
saturation concentration C* represents the concentration variation which is used to 
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calculate the total mass transfer coefficient over 45 minutes with respect to each dissolution 
speeds.  
The properties of the dissolution system, tablet properties and the values of these 
coefficients are presented in Tables 4.6, 4.7, and 4.8. respectively. 
It is seen that there is a gradual increase of the mass transfer coefficient during the 
dissolution process in both dissolution systems as the motion speed increased. This is 
consistent with the decrease in the tablet dimension which leads to change of the limit layer 
thickness as well as the existence of a solvent diffusion process in the granules.  
Comparing the values of the total mass transfer coefficient k at dissolution it is seen 
that an intensification of the hydrodynamic conditions by increasing the stirring rate have 
a favorable effect over the dissolution process. This resulted an increase in the k value. It 
is noticeable that as the motion speed increased, the mass transfer coefficient increased, 
however there was marked difference in values of the Minivessel dissolution system from 
that in one-liter standard system.  
It is noticeably that at the higher motion speed of 100 rpm,109.2 rpm 125 rpm,129.2 
rpm and 150 rpm in the Minivessel there exist a proportionate percentage difference 
between the mass transfer coefficient of the 5 dose 81mg aspirin in the standard system at 
100- rpm. This disparity between the values in both system could be attributed to the 
geometric di-similarity between the Minivessel and the standard system, in terms of the 
ratio of the height of the fluid to tank diameter and the position of the impeller relative to 
bottom of the vessels impeller diameter ratios, [7]. 
 
66 
Since the rate of dissolution of solids into liquids is a function of the power to 
volume ratio put into the fluid this will increase with scale-up. The standard USP2 system 
however operates in regime where the flow is incipient- turbulent and time dependent, the 
smaller vessel on the other hand displaces the dissolution system towards a laminar flow 
regime [22].  
The derivation of identical mass transfer coefficient at the predicted agitation speed 
by the former group was not obtained. This could be due to the utilization of a 
disintegrating tablet instead of a non- disintegrating tablet, that will ultimately explode into 
thousands of small particles of which a definite surface area is impractical to determine   It 
was however evident that a proportionate ratio of agitation speed, surface area and volume 
will produce equivalent dissolution profiles in both systems. The results from both system 
was also able to prove that the concentration, or the change in the mass with time compared 









A number of conclusions can be drawn from this work, as follows: 
1. Operating the USP 2 system and the Minivessel with the same dosage form in both 
systems is not an effective method to achieve similarity of dissolution profiles even 
if the two systems are operated at different agitation speeds. 
2. A more appropriate approach consists in operating the two systems with different 
amounts of drug so as to achieve similarity in both systems as far as ratio of tablet 
mass to liquid dissolution media and ratio of tablet surface area available for 
dissolution to liquid dissolution media are concerned.  Under these conditions, the 
dissolution curves in the two systems appear to be somewhat similar if the agitation 
speeds in the two systems is on the same order of magnitude. 
3. An even more effective approach to achieve dissolution profile similarity between 
the USP 2 and the Minivessel consists in operating the two systems so as to not 
only maintain the two above-mentioned ratios identical in the two systems but also 
to operate the USP 2 and the Minivessel at the agitation speeds predicted in a recent 
study by this group (Wang et al., 2017), i.e., at  50, 75, and 100 rpm in the USP 2 
and at the corresponding speed of 86.2, 109.7, and 129.2 rpm in the Minivessel, 
respectively. 
4. Experimental dissolution curves obtained in the two systems under these operating 
conditions appear to be very similar, as also quantitatively shown using the 
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difference factor f1 and the similarity factor f2 recommended by the Food and Drug 
Administration (FDA) to test the statistical similarity of two dissolution profiles. 
5. These results of this work were obtained with disintegrating tablets used for the 
rapid release of the drug substance, although the original work of Wang et al., 2017 
was based on the use of non-disintegrating slowly eroding tablets.  However, the 
results of this work indicate that their proposed approach appears to have a more 
general validity. 
6. This work was based on the use of tablets containing a specific drug product, 
namely aspirin.  Since the rationale for the use of the proposed method to obtain 
similarity of dissolution profiles in the two systems does not rely on the use of 
specific parameters related to the drug product, it can be expected that the results 
of this work are or more general validity. 
In summary, it can be concluded that appropriately operating Minivessel can result in 
dissolution profiles similar to those obtained in the USP 2.   
The results of this work could be of significant importance to dissolution scientists in 
the pharmaceutical industry and help them operate Minivessel, especially during the early 
stages of drug development, so as to predict future dissolution profiles of the same drug 















































   0 0 0 0 0 0 0 0 0 0 0 
  5 0.5613 0.5106 0.554 0.1837 0.1665 0.1812 11.3203 10.260 11.166 0.0043 
10 1.0883 0.970 0.9033 0.3626 0.3225 0.2998 22.3473 19.871 18.476 0.0141 
15 1.3543 1.280 1.2436 0.4530 0.4277 0.4154 27.9132 26.357 25.597 0.0086 
20 1.6596 1.486 1.604 0.5567 0.4977 0.5378 34.3020 30.668 33.137 0.0135 
25 1.901 1.7576 1.780 0.6386 0.5900 0.5978 39.3517 36.352 36.833 0.0122 
30 2.0926 1.9946 1.998 0.7037 0.6704 0.6717 43.3622 41.311 41.388 0.0089 
35 2.308 2.146 2.179 0.7768 0.7218 0.7332 47.8679 44.478 45.175 0.0135 
40 2.4923 2.314 2.328 0.8394 0.7790 0.7836 51.7249 48.000 48.286 0.0159 












































  0 0 0 0 0 0 0 0 0 0 0 
  5 0.98366 1.03766 0.724 0.324497 0.34269 0.237016 19.993 21.114 14.6035 0.0264 
10 1.644 1.74966 1.3975 0.546964 0.582563 0.463918 33.700 35.894 28.583 0.0276 
15 2.0536 2.135 1.7635 0.68498 0.712382 0.587223 42.205 43.892 36.1813 0.0305 
20 2.395 2.55833 1.98 0.799976 0.855003 0.660162 42.289 52.680 40.6754 0.0458 
25 2.6953 2.73033 2.333 0.889029 0.912949 0.779088 54.776 56.2507 48.0029 0.0333 
30 2.81266 2.84033 2.49 0.940687 0.9008 0.831981 57.959 58.534 51.2619 0.0310 
35 2.84833 2.893 2.683 0.952704 0.967752 0.897003 58.7001 59.627 55.2619 0.0173 
40 2.913 2.92033 2.767 0.97449 0.97696 0.925302 60.425 60.1947 57.0118 0.0138 
45 2.913 2.927667 2.854 0.97449 0.979431 0.954613 60.042 60.346 58.8178 0.0061 
 







































   0 0 0 0 0 0 0 0 0 0 0 
  5 2.0743 2.0346 1.646 0.6975 0.6840 0.5523 42.9786 42.1486 34.0300 0.0379 
10 2.633 2.6073 2.524 0.8872 0.8785 0.8503 54.6683 54.1312 52.3945 0.0089 
15 2.8476 2.8393 2.765 0.9601 0.9573 0.9322 59.1600 58.9856 57.4372 0.0072 
20 2.906 2.887 2.881 0.9799 0.9735 0.9714 60.3806 59.9830 59.8575 0.0020 
25 2.9276 2.945 2.921 0.9873 0.9932 0.9851 60.8339 61.1966 60.7014 0.0019 
30 2.944 2.9603 2.951 0.9928 0.9984 0.9953 61.1757 61.5175 61.329 0.0011 
35 2.944 2.9676 2.967 0.9982 1.0009 1.0008 61.1757 61.6709 61.663 0.0021 
40 2.944 2.9756 2.984 0.9928 1.0036 1.0064 61.1757 61.8383 62.0127 0.0033 











































0 0 0 0 0 0 0 0 0 0 0.0752 
5 1.683 2.4166 2.5673 0.5646 0.8138 0.8649 34.7903 50.1417 53.2942 0.0199 
10 2.604 2.7626 2,8736 0.8774 0.9311 0.9689 54.0615 57.3814 59.7040 0.0045 
15 2.9326 2.8736 2.9133 0.9890 0.9689 0.9824 60.9386 59.7040 60.5340 0.0085 
20 3.010 2.9033 2.9356 1.0153 0.9780 0.9900 62.5567 60.2620 61.0013 0.0057 
25 3.010 2.937 2.9593 1.0153 0.9905 0.9980 62.5567 61.0292 61.4965 0.0042 
30 3.010 2.952 2.9756 1.0153 0.9955 1.0036 62.5567 61.343 61.8383 0.0041 
35 3.010 2.952 2.984 1.0153 0.9955 1.0064 62.5567 61.343 62.0127 0.0041 
40 3.010 2.952 2.984 1.0153 0.9955 1.0064 62.5567 61.343 62.0127 0.0041 
45 3,010 2.952 2.984 1.0153 0.9955 1.0064 62.5567 61.343 62.0127 0.0041 
 







































0 0 0 0 0 0 0 0 0 0 0.0924 
5 1.7353 1.919 2.821 0.5824 0.6447 0.9511 35.8853 39.7284 58.6020 0.0438 
10 2.3063 2.6416 2.9133 0.7763 0.8902 0.9824 47.8331 54.8457 60.5340 0.0086 
15 2.855 2.9593 2.9356 0.9626 0.9980 0.9900 59.3135 61.4966 61.0013 0.0035 
20 2.983 3.010 2.9593 1.0068 1.0153 0.9980 62.0336 62.5567 61.496 0.0023 
25 3.010 3.010 2.9833 1.0153 1.0153 1.0065 62.5567 62.5567 62.0196 0.0023 
30 3.010 3.010 2.9833 1.0153 1.0153 1.0065 62.5567 62.5567 62.0196 0.0023 
35 3.010 3.010 2.9833 1.0153 1.0153 1.0065 62.5567 62.5567 62.0196 0.0023 
40 3.010 3.010 2.9833 1.0153 1.0153 1.0065 62.5567 62.5567 62.0196 0.0023 




Table A.6 Dissolution Profile for Half Dose 325 mg Aspirin in USP 2 (50 rpm) 
 







































0 0 0 0 0 0 0 0 0 0 0 
5 0.4890 0.4410 0.3900 0.1597 0.1433 0.1264 50.2089 45.0829 39.7433 0.1214 
10 0.5656 0.5770 0.4557 0.1857 0.1895 0.1483 58.6067 59.6067 46.6492 0.1509 
15 0.6987 0.6500 0.5637 0.2309 0.2143 0.1850 72.5997 67.4025 58.1827 0.1788 
20 0.7523 0.7280 0.6017 0.2491 0.2408 0.1979 78.3309 75.7323 62.2408 0.1969 
25 0.7417 0.7590 0.7270 0.2455 0.2514 0.2405 77.1918 79.0429 75.6255 0.1998 
30 0.9494 0.7807 0.7990 0.3160 0.2587 0.2469 99.3726 81.3567 83.3146 0.2305 
35 0.9053 0.7870 0.8927 0.3011 0.2609 0.2968 94.6701 82.0330 93,3175 0.2256 
40 0.9317 0.9103 0.9000 0.3099 0.3027 0.2992 974824 95.2042 94.1006 0.2463 



































Avg Std. Dev. 
C/C* 
0 0 0 0 0 0 0 0 0 0 0 
5 0.5387 0.6123 5093 0.1760 0.2010 0.11601 87.1442 99.5298 82.2126 0.0660 
10 0.6957 0.701 0.6183 0.2293 0.2316 0.2030 113.5388 114,4354 100.5376 0.0598 
15 0.694 0.7113 0.6830 0.2287 0.2347 0.2250 113.246 116.1726 111.4093 0.0170 
20 0.7413 0.7083 0.6577 0.2449 0.2337 0.2164 121.2162 115.6683 107.1502 0.0501 
25 0.795 0.6903 0.6777 0.2631 0.2275 0.2230 130.2386 112.6421 112.992 0.0832 
30 0.72 0.7000 0.6920 0.2376 0.2308 0.2281 17.6297 114.2673 111.8016 0.0179 
35 0.766 0.7097 0.6853 0.2532 0.2341 0.2258 125.3631 115.8925 109.3358 0.0511 
40 0.713 0.6643 0.6707 0.2352 0.2187 0.2208 116.4529 108.2719 109.3358 0.0339 
45 0.766 0.6790 0.6637 0.2532 0.2237 0.2184 125.3631 110.7368 108.1590 0.0707 
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0 0 0 0 0 0 0 0 0 0 0 
5 0.9643 1.0324 0.9063 0.3205 0.3443 0.3009 77.436 83.1786 72.678 0.0350 
10 1,1593 1.196 1.0996 0.3868 0.3992 0.3665 94.432 96.440 88.537 0.0284 
15 1.2373 1.2617 1.121 0.4133 0.4215 0.3737 99.850 101.826 90.287 0.0468 
20 1.2593 1.2727 1.1453 0.4208 0.4252 0.3820 101.635 102.728 92.283 0.0439 
25 1.250 1.2533 1.1836 0.4176 0.4187 0.3950 100.869 101.142 95.428 0.0247 
30 1.2533 1.3306 1.1793 0.4194 0.4449 0.3936 101.307 107.486 95.072 0.0414 
35 1.2203 1.2583 1.225 0.4075 0.4204 0.4091 98.436 101.553 98.819 0.0130 
40 1.2537 1.3167 1.196 0.4188 0.4402 0.3992 101.170 106.338 96.44 0.0334 




Table B.1 Dissolution Profile Single Dose 81mg Aspirin Minivessel (50 rpm) 
 





































0 0 0 0 0 0 0 0 0 0 0 
5 0.4070 0.5323 0.462 0.1114 0.1523 0.1293 13.756 18.809 15.973 0.0175 
10 0.8470 1.007 0.7163 0.2551 0.3073 0.2124 31.497 37.984 26.228 0.0403 
15 1.2640 1.233 0.9776 0.3913 0.3811 0.2978 48.311 47.061 36.766 0.0485 
20 1.5430 1.6363 1.3306 0.4824 0.5129 0.4130 59.560 63.324 50.999 0.0454 
25 1.7320 1.8186 1.5586 0.5441 0.5724 0.4875 67.181 70.676 60.192 0.0388 
30 1.9523 1.9023 1.787 0.6161 0.5998 0.5621 76.065 74.049 69.399 0.0251 
35 1.8937 1.993 1.781 0.5969 0.6294 0.5601 73.700 77.705 69.157 0.0290 
40 2.1013 2.0593 1.9166 0.6647  0.6510 0.6044 82.073 80.380 74.627 0.0293 





































0 0 0 0 0 0 0 0 0 0 0 
5 0.2693 0.5497 0.426 0.0648 0.1580 0.1176 8.011 19.509 14.522 0.0400 
10 0.564 0.7483 0.868 0.1483 0.2229 0.2619 18.312 27.519 32.344 0.0516 
15 0.9273 0.961 0.8953 0.2445 0.2924 0.2709 30.187 36.094 33.446 0.0203 
20 1.2043 1.414 1.042 0.3457 0.4403 0.3188 42.686 54.359 39.360 0.0592 
25 1.3986 1.5596 1.3183 0.4404 0.4879 0.4091 54.379 60.232 50.502 0.0346 
30 1.5863 1.7373 1.4813 0.4799 0.5459 0.4623 59.285 67.396 57.074 0.0410 
35 1.683 1.761 1.5873 0.5613 0.5536 0.4969 69.298 68.351 61.348 0.0332 
40 1.7983 1.857 1.6217 0.5612 0.5849 0.5081 69.278 72,222 62.732 0.0356 
45 1.825 1.903 1.767 0.5961 0.6000 0.5556 73.593 74.076 68.593 0.0232 
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0 0 0 0 0 0 0 0 0 0 0 
5 0.1743 0.190 0.1956 0.0354 0.04044 0.0424 4.3749 4.9932 5.2351 0.0523 
10 0.375 0.395 0.358 0.1009 0.1075 0.0954 12.4660 13.2725 11.7806 0.1178 
15 0.8823 0.845 0.794 0.2667 0.2544 0.2378 32.9222 31.4169 29.3605 0.2936 
20 1.2976 1.281 1.1803 0.4023 0.3968 0.3639 49.6688 48.9667 44.9379 0.4493 
25 1.589 1.539 1.5467 0.4974 0.4810 0.4836 61.4157 59.3862 59.7088 0.5970 
30 1.8107 1.808 1.7593 0.5698 0.5691 0.5530 70.3535 70.2594 68.2837 0.6828 
35 1.916 1.982 1.944 0.6042 0.6257 06134 74.6006 77.2484 75.7297 0.7572 
40 2.054 1.960 2.077 0.6493 0.6186 0.6568 80.1649 76.3748 81.0923 0.8109 
45 2.1627 2.198 2.204 0.6848 0.6963 0.6983 84.5465 85.9712 86.2131 0.8621 
 






































0 0 0 0 0 0 0 0 0 0 0 
5 0.2987 0.1843 0.496 0.0760 0.0387 0.1405 9.3882 4.7782 17.3449 0.0309 
10 0.986 0.613 1.1593 0.3005 0.1787 0.3571 37.1021 22.0624 44.0911 0.0637 
15 1.4193 1.2243 1.683 0.4421 0.3783 0.5281 54.5746 46.7120 65.2059 0.0310 
20 1.805 1.6963 2.026 0.5680 0.5325 0.6402 70.1251 65.7435 79.036 0.0233 
25 2.0637 2.0113 2.249 0.6525 0.6354 0.7130 80.5548 78.4446 88.0276 0.0364 
30 2.2033 2.1533 2.310 0.6981 0.6817 0.7329 86.1862 84.1702 90.0757 0.0528 
35 2.2527 2.3373 2.399 0.71422 0.7418 0.7620 88.1754 91.5893 94.0757 0.0608 
40 2.3037 2.3613 2.3737 0.7309 0.7497 0.7537 90.2318 92.5569 93.0542 0.0712 










































0 0 0 0 0 0 0 0 0 0 0 
5 0.2727 0.192 0.1977 0.0675 0.0412 0.0430 8.33 5.087 5.315 0.0112 
10 0.9437 0.7913 0.7533 0.2867 0.2369 0.2245 35.39 27.72 27.720 0.0248 
15 1.4957 1.523 1.3897 0.4669 0.4759 0.4327 57.65 53.38 53.378 0.0173 
20 2.1217 1.9357 1.8507 0.6714 0.6107 0.5829 82.89 71.96 71.966 0.0331 
25 2.2947 2.1203 2.1333 0.7279 06710 0.6751 89.86 83.35 83.350 0.0253 
30 2.3807 2.2547 2.346 0.7560 0.7148 0.7448 93.34 91.95 91.952 0.0157 
35 2.475 2.3687 2.435 0.7868 0.7521 0.7737 97.14 95.53 95.527 0.0125 
40 2.4883 2.4733 2.497 0.7912 0.7862 0.7939 97.68 98.01 98.013 0.0027 
45 2.4373 2.5333 2.491 0.7745 0.8058 0.7921 95.62 97.78 97.785 0.0109 
 



































0 0 0 0 0 0 0 0 0 0 0 
5 0.3753 0.1945 0.3183 0.1019 0.0420 0.0824 12.4794 5.1881 10.1811 0.0272 
10 1.5446 1.615 1.484 0.4829 0.5059 0.4631 59.6281 62.4641 57.1820 0.0180 
15 2.105 2.109 2.0683 0.6659 0.6672 0.6540 82.2213 82.3826 80.7429 0.0069 
20 2.2706 2.167 2.2136 0.7201 0.6862 0.7014 88.9012 84.7212 86.6029 0.0143 
25 2.3576 2.3675 2.3583 0.7485 0.7517 0.7487 92.4091 92.8056 92.4360 0.0017 
30 2.471 2.402 2.4243 0.7855 0.7529 0.7702 96.9788 94.1966 95.0971 0.0103 
35 2.482 2.407 2.4713 0.7891 0.7646 0.7856 97.4223 94.3983 96.9922 0.0124 
40 2.483 2.39 2.4846 0.7894 0.7590 0.7899 97.4626 93.7128 97.5298 0.0168 




Table 7.B Dissolution Profile Single Dose 81mg Aspirin Minivessel (129.2 rpm) 
 
 





































0 0 0 0 0 0 0 0 0 0 0 
5 0.4523 0.2013 0.2077 0.1236 0.0442 0.04632 15.584 5.4636 5.7190 0.0359 
10 1.693 1.6497 1.6073 0.5314 0.5173 0.5034 65.6091 63.8619 62.1549 0.0093 
15 2.190 2.0913 2.1993 0.6937 0.6615 0.6968 85.6486 81.6703 86.0250 0.0149 
20 2.333 2.2503 2.3987 0.7404 0.7134 0.7619 91.4145 88.0813 94.0622 0.0149 
25 2.4277 2.3663 2.4553 0.7713 0.7513 0.7804 95.2316 92.7585 96.3471 0.0167 
30 2.4467 2.4083 2.4687 0.7776 0.7651 0.7947 95.9977 94.4521 96.8848 0.0109 
35 2.4643 2.4187 2.4343 0.7833 0.7684 0.7736 96.7100 94.8687 95.5004 0.0071 
40 2.5017 2.421 2.494 0.7955 0.7692 0.7930 98.2153 94.9628 97.9062 0.0054 


































0 0 0 0 0 0 0 0 0 0 0 
5 0.279 0.6073 0.430 0.0696 0.1768 0.11893 8.595 21.8339 14.6837 0.0453 
10 1.7226 1.8253 1.5623 0.5411 0.5746 0.48875 66.8053 70.9449 60.3405 0.0379 
15 2.0876 2.0966 2.127 0.6603 0.6632 0.67317 81.5524 81.8853 83.1084 0.0062 
20 2.2973 2.248 2.2413 0.7288 0.7126 0.71051 89.9764 87.9872 87.7184 0.0094 
25 2.4086 2.3826 2.3976 0.7651 0.7566 0.76157 94.4655 93.4171 94.0219 0.0036 
30 2.519 2.415 2.4193 0.8012 0.7672 0.76865 98.9142 94.7208 94.8955 0.0182 
35 2.5066 2.4926 2.4616 0.7971 0.7926 0.78248 98.4169 97.8524 96.6025 0.0068 
40 2.4723 2.420 2.485 0.7859 0.7688 0.79010 97.0326 94.9224 97.5433 0.0105 
45 2.4943 2.4667 2.502 0.7931 0.7841 0.79565 97.9196 96.8041 98.2297 0.0056 
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Table 9.B Dissolution Profile Single Dose 81mg Aspirin USP2 (50 rpm) 
 
 



































0 0 0 0 0 0 0 0 0 0 0 
5 0.2206 0.2436 0.2857 0.0506 0.0580 0.0717 31.2159 35.8528 44.3202 0.0479 
10 0.3650 0.4357 0.3580 0.0977 0.1208 0.0954 60.3142 74.5609 58.9029 0.0665 
15 0.4240 0.4450 0.4420 0.1169 0.1238 0.1228 72.2089 76.4426 75.8378 0.0175 
20 0.4820 0.4833 0.4670 0.1359 0.1363 0.1310 83.9019 84.1707 80.8779 0.0140 
25 0.5383 0.6417 0.6520 0.1543 0.1880 0.1914 95.2591 116.0916 118.1748 0.0972 
30 0.6277 0.5860 0.5927 0.1834 0.1699 0.1721 113.2691 104.8689 106.2129 0.0343 
35 0.6220 0.6590 0.6117 0.1816 0.1937 0.1783 112.1267 119.586 110.0434 0.0377 
40 0.6036 0.6543 0.6376 0.1756 0.1922 0.1868 108.4306 118.6452 115.2851 0.0379 



































0 0 0 0 0 0 0 0 0 0 0 
5 0.2303 0.2017 0.2417 0.0537 0.0443 0.0663 5.7428 6.6329 5.4771 0.0061 
10 0.6790 0.6547 0.6317 0.2002 0.1944 0.2472 18.4802 24.7236 23.9957 0.0068 
15 1.0270 1.0180 0.9083 0.3139 0.3109 0.3876 29.8677 38.7553 38.3924 0.0075 
20 1.2880 1.3163 1.2833 0.3992 0.4084 0.4928 39.7637 49.2791 50.4215 0.0054 
25 1.500 1.9047 1.4517 0.4684 0.4654 0.5783 45.2614 57.8272 57.4508 0.0078 
30 1.6757 1.6663 1.5327 0.5258 0.5227 0.6491 47.9069 64.9102 64.5339 0.0248 
35 1.7677 1.7033 1.6427 0.5548 0.5436 0.6849 51.4994 68.4988 67.1144 0.0188 
40 1.8743 1.7987 1.7130 0.5907 0.5659 0.7292 53.7966 72.9206 69.8697 0.0221 
45 1.9203 1.8447 1.8180 0.6057 0.5809 0.7477 57.2259 74.7754 71.7245 0.0159 
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0 0 0 0 0 0 0 0 0 0 0 
5 0.2207 0.178 0.2947 0.0506 0.0365 0.0747 6.2431 4.5094 9.2269 0.0191 
10 0.885 0.881 1.014 0.2675 0.2663 0.3097 33.0297 32.8819 38.2311 0.02166 
15 1.4267 1.550 1.5037 0.4529 0.4848 0.4695 55.9186 59.8567 57.975 0.0076 
20 1.8523 1.977 1.7647 0.5834 0.6243 0.5549 72.0335 77.0737 68.4988 0.0347 
25 2.0253 2.108 1.9645 0.6399 0.6670 0.6202 79.0009 82.3557 76.5629 0.02346 
30 2.136 2.188 2.0987 0.6761 0.6931 0.6639 83.4713 85.568 81.9659 0.01459 
35 2.234 2.240 2.187 0.7081 0.7107 0.6928 87.4227 87.6781 85.5277 0.0087 
40 2.2673 2.280 2.242 0.7190 0.7231 0.7107 88.7667 89.2775 87.7453 0.0062 
45 2.3343 2.323 2.279 0.7409 0.7371 0.7229 91.4683 91.0113 89.2506 0.0071 
 





































 0 0 0 0 0 0 0 0 0 0 0 
 5 0.410 0.3196 0.1633 0.1124 0.0829 0.0318 13.88 10.23 3.93 0.0096 
10 1.7237 1.6537 1.389 0.5414 0.5186 0.4321 66.845 64.02 53.351 0.0291 
15 2.047 2.026 1.8577 0.64071 0.6402 0.5852 79.882 79.03 72.248 0.3818 
20 2.2603 2.2627 2.059 0.7167 0.7175 0.6509 88.48 88.57 80.366 0.5395 
25 2.3217 2.3593 2.346 0.7367 0.7491 0.7447 90.95 92.47 91.938 0.5963 
30 2.3333 2.421 2.405 0.7405 0.7691 0.7639 91.42 94.96 94.317 0.7124 
35 2.3453 2.446 2.4317 0.7444 0.7773 0.7726 91.91 95.97 95.392 0.7338 
40 2.353 2.4483 2.444 0.7469 0.7781 0.7767 92.22 96.06 95.890 0.7425 




Figure 1.C Dissolution Profile Half Dose 325mg Aspirin USP2(50 rpm). 
 
 




Figure 3.C Dissolution Profile Full Dose 325mg Aspirin USP2 (100 rpm). 
 
 





Figure 5.C Dissolution Profile Half Dose 325mg Aspirin Minivessel (75 rpm). 
 
 






Figure 7C. Dissolution Profile Half Dose 325mg Aspirin Minivessel (125 rpm). 
 
 







Figure 1.D Dissolution Profile Single Dose 81mg Aspirin USP2 (50 rpm, 500 rpm).  
 
 






Figure 3.D Dissolution Profile 5 Dose 81mg Aspirin usp2 (75 rpm, 500ml). 
 
 





Figure 5.D Dissolution Profile Single Dose 81mg Aspirin Minivessel. (50 rpm,). 
 
 






Figure 7.D Dissolution Profile Single Dose 81mg Aspirin Minivessel. (86.3 rpm). 
 
 






Figure 9.D Dissolution Profile Single Dose 81mg Aspirin Minivessel. (109.7Rpm. 
 
 






Figure 11.D Dissolution Profile Single Dose 81mg Aspirin Minivessel. (129.2 rpm) 
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